Fundraising Activities - The company issued 517,600,000 new shares at a subscription price of approximately HK$0.1855 per share, raising a total of HK$96,014,800[1]. - All conditions precedent under the subscription agreement were fulfilled, and the completion took place on February 6, 2023[4]. - The intended use of net proceeds from the fund-raising activities included approximately HK$18 million for existing electronic products and related supply chain services[6]. - The actual use of net proceeds for developing the Group's assisted reproduction medical technology business was approximately HK$5.9 million[8]. - The company has raised approximately HK$29.2 million for general working capital through share placements[8]. - The remaining unutilized net proceeds as of December 31, 2022, are estimated to be HK$21.2 million, expected to be fully utilized in 2023[16]. Financial Performance - Revenue for 2022 decreased to HK$529.3 million, down 21.6% from HK$675.5 million in 2021[114]. - Loss for the year was HK$52.0 million, compared to a loss of HK$47.1 million in 2021[114]. - Revenue from the EMS and Distribution business segment decreased by approximately HK$120.5 million, or 34.6%, for the year ended December 31, 2022[12]. - The Group recorded overall impairment losses of approximately HK$12.5 million for the year ended 31 December 2022, a slight decrease from HK$12.6 million in 2021[157]. - The Group's loss attributable to owners of the Company was approximately HK$54.0 million for the year ended 31 December 2022, with a net loss margin of approximately 10.2%[159]. Revenue Breakdown - Revenue from the EMS and Distribution business segment decreased by approximately HK$120.5 million or 34.6% due to reliance on major customers from Western countries[130]. - Revenue from the Real Estate Supply Chain Services increased by approximately HK$2.8 million or 60.5% as a result of favorable government policies aimed at boosting the real estate market[130]. - Revenue from major European countries totaled approximately HK$228.3 million, accounting for 43.1% of the Group's revenue, a decrease from 51.6% in 2021[155]. - The U.S. market contributed approximately HK$102.6 million in revenue, representing 19.4% of the Group's total revenue, an increase from 12.1% in 2021[155]. Cost and Expenses - Cost of sales decreased by 19.4% from HK$530.6 million in 2021 to HK$427.9 million in 2022, primarily due to a decrease in sales volume and a significant increase in material costs[157]. - Gross profit decreased by 30.0% from HK$144.9 million to HK$101.4 million, with a gross profit margin decline of 2.2% attributed to rising material prices and reduced sales[157]. - Administration expenses decreased to HK$105.0 million in 2022 from HK$154.2 million in 2021, representing approximately 19.8% of the Group's revenue[157]. - Selling and distribution expenses were HK$30.0 million in 2022, accounting for approximately 5.7% of the Group's revenue, compared to 4.3% in 2021[157]. Corporate Governance - The Company is committed to maintaining high standards of corporate governance to protect shareholder interests[22]. - The new Corporate Governance Code came into effect on January 1, 2022, applicable to the financial year starting on that date[23]. - The Company has complied with the Corporate Governance Code throughout the year ended December 31, 2021, with a noted deviation regarding the separation of roles of chairman and chief executive officer[24]. - The board consists of five executive directors and three independent non-executive directors, with the latter accounting for more than one-third of the board[33]. - All independent non-executive directors confirmed their independence as per Rule 3.13 of the Listing Rules[46]. Risk Management - The company remains vigilant in maintaining effective controls and procedures for loan approvals and credit monitoring[13]. - The Group has established strict credit policies and controls to mitigate credit risks associated with its lending operations[150]. - Management regularly reviews groupings of debtors to ensure they share similar credit risk characteristics[151]. Market Conditions - The company has experienced increased costs in transportation of raw materials and finished products due to geopolitical tensions[12]. - The geopolitical situation, particularly the ongoing war in Ukraine, has further complicated the economic landscape, impacting investor confidence and operational costs[130]. - The management anticipates a recovery in the global economy following the end of the three-year epidemic, with activities in retail, project investment, and business meetings returning to normal[17]. Employee and Share Options - As of December 31, 2022, the Group employed approximately 1,025 employees across various operating units in Hong Kong, the U.S.A., and the PRC[173]. - The Group's share options outstanding as of December 31, 2022, include 5,333,092 options for executive directors and 20,316,607 options for employees[172]. - A total of 53,328,000 share options were granted during the year ended December 31, 2022, with all of them lapsed or cancelled by the end of the year[172].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Link-Asia International MedTech Group Limited 環 亞 國 際 醫 療 科 技 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1143） 有關截至二零二二年十二月三十一日止年度之 經審核年度業績公告之 補充公告 茲提述環亞國際醫療科技集團有限公司（「本公司」）日期為二零二三年三月三十一 日之公告，內容有關截至二零二二年十二月三十一日止年度之年度業績公告（「業 績公告」）。除文義另有所指外，本公告所用詞彙與業績公告所界定者具有相同涵 義。 除業績公告提供之資料外，董事會謹此提供有關截至二零二二年十二月三十一日 止年度購買、出售或贖回本公司上市證券之進一步資料。 購買、出售或贖回上市證券 截至二零二二年十二月三十一日止年度，本公司或任何附屬公司概無購買、出售 或贖回本公司之上市證券。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容 概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對 因本公告全部或任何部份內容而產生或因倚賴該等內容而引致之任何損 失承擔任何責任。 Link-Asia International MedTech Group Limited 環 亞 國 際 醫 療 科 技 集 團 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1143） 截 至 二 零 二 二 年 十 二 月 三 十 一 日 止 年 度 之 經 審 核 年 度 業 績 公 告 環亞國際醫療科技集團有限公司（「本公司」）董事會（「董事會」）宣佈本公司 及其附屬公司（「本集團」）截至二零二二年十二月三十一日止年度之經審 核綜合業績及截至二零二一年十二月三十一日止年度的比較數字如下： 綜合損益及其他全面收益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 收入 4 529,251 675,523 ...

Financial Performance - For the six months ended June 30, 2022, the Group recorded total revenue of HK$281.9 million, a decrease of approximately 13.2% from HK$324.8 million for the same period in 2021[23]. - The revenue from the EMS business decreased by 9.4% to HK$270.1 million, while revenue from the Distribution of Communications Products business decreased by 64.0% to HK$8.6 million[18]. - Gross profit decreased by approximately 30.4% from HK$70.6 million for the six months ended June 30, 2021, to approximately HK$49.1 million for the same period in 2022[23]. - The loss attributable to owners of the Company was approximately HK$13.5 million for the period ended June 30, 2022, improving from a loss of HK$32.0 million in 2021[30]. - The company reported a loss for the period of HK$12,824,000, compared to a loss of HK$32,129,000 in the previous year, indicating an improvement[85]. - Total comprehensive income for the period was a loss of HK$10,263,000, compared to a loss of HK$29,113,000 in the previous year, indicating a 65% improvement[89]. Revenue Breakdown - Revenue contributions from major European countries totaled approximately HK$131.1 million, accounting for 46.5% of the Group's total turnover for the six months ended June 30, 2022[22]. - The United States market contributed approximately HK$47.1 million in revenue, accounting for 16.7% of total revenue[22]. - The People's Republic of China, including Hong Kong, accounted for approximately HK$26.8 million in revenue[22]. - For the six months ended June 30, 2022, total revenue from external customers was HK$281,893,000, with the electronic manufacturing services segment contributing HK$270,054,000[158]. Cost and Expenses - The increase in material cost price levels due to supply chain chaos and trade disputes between China and the USA contributed to the gross profit decline[23]. - Administrative expenses decreased to HK$53,396,000 from HK$71,696,000, reflecting cost control measures[85]. - The cost of goods sold for the period was HK$231,476,000, compared to HK$251,909,000 in the previous year[192]. - Employee benefits expense, including directors' emoluments, totaled HK$87,200,000 for the six months ended June 30, 2022, down from HK$95,787,000 in the same period of 2021[192]. Cash Flow and Liquidity - As of June 30, 2022, the Group maintained bank and cash balances totaling approximately HK$190.0 million, up from HK$145.6 million as of December 31, 2021[18]. - The company's cash and bank balances rose to HK$189,996,000, up from HK$145,574,000, marking an increase of approximately 30%[91]. - For the six months ended June 30, 2022, the net cash generated from operating activities was HK$33,419,000, compared to a net cash used of HK$19,969,000 in the same period of 2021[102]. Shareholder Information - As of June 30, 2022, the total number of issued shares is 1,207,691,855, an increase from 924,363,855 shares as of December 31, 2021[35]. - The Group has 30,982,791 outstanding share options under the New Share Option Scheme as of June 30, 2022[54]. - The Company has not recommended the payment of an interim dividend for the period, consistent with the previous year (2021: nil)[59]. Governance and Compliance - The Company has complied with the Corporate Governance Code provisions throughout the six months ended 30 June 2022, except for the deviation regarding the roles of chairman and chief executive officer[58]. - The Audit Committee, consisting of three independent non-executive Directors, has reviewed the accounting principles and unaudited condensed consolidated interim financial statements for the six months ended 30 June 2022[59]. - The Company has made specific inquiries to all Directors regarding compliance with the Model Code for Securities Transactions, and all confirmed adherence throughout the reporting period[58]. Future Outlook and Strategy - The Group's management is focused on developing existing core businesses and exploring new business opportunities to maintain a strong financial position amid an uncertain global economic environment[18]. - The Group plans to focus on the high-end medical and health service business in the coming years, while remaining cautious due to the uncertain economic environment caused by COVID-19 variants[54]. - The Group's future strategy includes a focus on the EMS and Distribution of Communication Products segment to ensure stable cash flow[54]. Segment Performance - The segment profit for electronic manufacturing services was HK$6,331,000, while the communications products segment reported a profit of HK$3,456,000[158]. - The total segment assets as of June 30, 2022, amounted to HK$671,711,000, with electronic manufacturing services holding HK$463,987,000[158]. - The total loss of reportable segments for the six months ended June 30, 2022, was HK$9,295,000, a significant improvement from a loss of HK$28,172,000 in the same period of 2021[167].

Financial Performance - The Group's revenue for the year ended December 31, 2021, was approximately HK$675.5 million, an increase from HK$595.0 million in 2020, representing a growth of 13.9%[9] - The revenue from the EMS segment increased to approximately HK$630.0 million, while the revenue from the Distribution of Communication Products businesses slightly increased to approximately HK$40.3 million during the same period[22] - The loss for the year was HK$47.1 million, a significant improvement compared to a loss of HK$173.1 million in 2020, indicating a reduction in loss by 72.8%[9] - Loss per share improved to HK$7.794 from HK$46.119 in the previous year, reflecting a substantial decrease in per-share loss[9] - Total assets increased to HK$678.0 million from HK$657.4 million, while total liabilities decreased to HK$312.0 million from HK$361.5 million, showing a healthier financial position[9] - The Group's total revenue for the year ended December 31, 2021, was approximately HK$675.5 million, an increase of approximately HK$80.5 million from HK$595.0 million in 2020, representing a growth of about 13.5%[39] - Revenue from the electronic manufacturing services segment increased to approximately HK$630 million for the year ended December 31, 2021[24] - Revenue from the distribution of communication products business slightly increased to approximately HK$40.3 million for the year ended December 31, 2021[24] - The Group's revenue growth rate for the EMS and Distribution of Communication Products segments was approximately 15.5%[40] - Revenue from the Real Estate Supply Chain Services business was approximately HK$4.6 million in 2021, down from HK$14.2 million in 2020, significantly impacted by COVID-19 border controls[44] - Cost of sales increased by approximately 20.5% from HK$440.3 million in 2020 to HK$530.6 million in 2021, in line with revenue growth[49] - Gross profit decreased by approximately 6.3% from HK$154.7 million in 2020 to HK$144.9 million in 2021, due to lower gross profit margins in the EMS and Distribution of Communication Products segments[49] Operational Efficiency - Average inventory turnover days were 72.8 days, slightly up from 71.5 days in 2020, indicating stable inventory management[9] - Average trade receivable turnover days improved to 88.5 days from 90.9 days, suggesting better collection efficiency[9] - Selling and distribution expenses were approximately HK$29.2 million for the year ended 31 December 2021, accounting for about 4.3% of the Group's revenue, down from 9.5% in 2020[53] - Administrative expenses amounted to approximately HK$154.2 million, representing 22.8% of revenue for the year ended 31 December 2021, compared to 29.9% in 2020[53] - Research and development expenditure increased slightly to approximately HK$15.0 million for the year ended 31 December 2021, up from HK$13.9 million in 2020[53] Market Challenges and Opportunities - The Group faced challenges in the real estate supply chain services due to epidemic prevention policies, which affected revenue expectations[22] - The overall economic recovery in China contributed positively to the Group's performance, as it was the only major economy to achieve positive growth in the previous year[22] - The Group is exploring the assisted reproductive market through mergers and acquisitions, investment, and joint venture cooperation due to the liberalization of China's fertility policies[39] - The Group has signed cooperation agreements with assisted reproductive medical experts and institutions to reserve assisted reproductive medical technology[29] - The Group aims to implement projects that integrate electronic business and medical business to enhance operational efficiency[39] - The company is optimistic about the high-end medical and health service business due to China's liberalization of fertility policies[134] - The ongoing COVID-19 pandemic is expected to have long-term effects on global supply chains and economic conditions, influencing the company's strategic decisions[134] - The company plans to resume its entry into the Real Estate Supply Chain Services business to meet the housing demand of young homebuyers in Southeast Asia[135] Financial Position and Cash Flow - As of December 31, 2021, the Group had bank and cash balances totaling approximately HK$145.6 million, down from HK$167.7 million in 2020[39] - The Group's current ratio improved to 2.0 times as of 31 December 2021, compared to 1.5 times in 2020[56] - Approximately HK$101.0 million was used in operating activities in 2021, with net cash generated from investing activities at approximately HK$3.5 million and financing activities at approximately HK$74.6 million[60] - In 2021, cash used in operating activities was approximately HK$101 million[61] - Capital expenditure for 2021 amounted to approximately HK$22.1 million, primarily for the acquisition of plant and machinery[65][66] - As of December 31, 2021, capital commitments were approximately HK$0.4 million[66] - The Group held listed equity investments of approximately HK$1.2 million as of December 31, 2021, with no dividend income received during 2020 and 2021[69] Corporate Governance - The company has adopted a new corporate governance code effective from January 1, 2022, which applies to the fiscal year starting from that date[149] - The company has complied with the corporate governance code provisions except for a deviation from provision A.2.1 regarding the separation of the roles of chairman and chief executive officer[149] - The board currently consists of four executive directors and three independent non-executive directors, with the latter accounting for more than one-third of the board[157] - The board's primary duty is to ensure the company's viability and manage it in the best interests of shareholders while considering other stakeholders[164] - The company has established internal guidelines for matters requiring board approval, including strategic plans and major investments[164] - The Board is responsible for ensuring the company's sustainability and managing it in the best interests of shareholders while considering other stakeholders[165] - The Audit Committee was established on December 31, 2010, and as of December 31, 2021, it comprised three independent non-executive Directors[192] - The primary duties of the Audit Committee include reviewing and supervising the financial reporting process and internal control system of the Group[196] Risk Management - The Group's financial condition and business prospects may be affected by various risks and uncertainties, including market, foreign exchange, interest rate, and liquidity risks[115] - The Group's liquidity risk management involves monitoring cash flows and maintaining an adequate level of cash and cash equivalents to meet obligations[121] - The Group's operational risk management is guided by standard operating procedures and regular assessments of key operational exposures[126] - The Group considers managing interest rate risk through various cost-effective means when appropriate[120] - The Group has not identified any significant non-compliance with applicable laws and regulations during the year[109] Share Issuance and Proceeds - The company successfully placed 85,580,000 shares at HK$0.35 per share, generating net proceeds of approximately HK$29.2 million[131] - A subsequent placement of 102,704,000 shares at HK$0.224 per share resulted in net proceeds of approximately HK$22.2 million[131] - On November 23, 2021, the company issued 308,121,285 rights shares at HK$0.2 per share, receiving net cash proceeds of approximately HK$58.7 million[132] - The intended use of the net proceeds from the Rights Issue includes approximately HK$34.2 million for expanding the Group's product range under EMS and Distribution Products, HK$17.1 million for potential merger and acquisition opportunities, and HK$7.4 million for general corporate and working capital[97] - The remaining unutilized net proceeds of approximately HK$29.9 million is estimated to be fully utilized before December 31, 2022[108]

[Corporate Information](index=3&type=section&id=Corporate%20Information) - The report details the company's core management, board members, registered office, Hong Kong and mainland China office addresses, and principal bankers[4](index=4&type=chunk)[6](index=6&type=chunk) [Management Discussion and Analysis](index=5&type=section&id=Management%20Discussion%20and%20Analysis) [Business Overview](index=5&type=section&id=BUSINESS%20OVERVIEW) In H1 2021, the Group's mainland China operations remained stable amid a challenging global environment, achieving significant revenue growth and a narrowed loss Key Performance Indicators for H1 2021 | Indicator | H1 2021 | H1 2020 | Change YoY | | :--- | :--- | :--- | :--- | | **Total Revenue** | HK$324.8 million | HK$260.0 million | +24.9% | | **Loss Attributable to Equity Holders** | HK$32.0 million | HK$69.9 million | -54.2% | | **Bank and Cash Balances (at period end)** | HK$208.6 million | - | - | Revenue Performance by Business Segment | Business Segment | H1 2021 Revenue | H1 2020 Revenue | Change YoY | | :--- | :--- | :--- | :--- | | **Electronic Manufacturing Services (EMS)** | HK$298.0 million | HK$231.2 million | +28.9% | | **Distribution of Communication Products** | HK$23.9 million | HK$15.8 million | +51.3% | | **Real Estate Supply Chain Services** | HK$2.6 million | HK$12.7 million | -79.5% | | **Investment in Securities and Other Assets** | HK$0.3 million | HK$0.3 million | 0% | - The company strategically entered the high-end healthcare services sector by establishing a joint venture in June 2021 to develop the endometrial stem cell business[11](index=11&type=chunk) [Geographical Analysis](index=6&type=section&id=Geographical%20Analysis) The Group's revenue is primarily derived from the European market, with a significant increase in contribution from the US market Revenue Distribution by Geographical Region | Region | H1 2021 Revenue | % of Total Revenue (2021) | % of Total Revenue (2020) | | :--- | :--- | :--- | :--- | | **Major European Countries** | HK$178.0 million | 54.8% | 53.8% | | **The United States** | HK$34.3 million | 10.6% | 6.4% | | **China (including Hong Kong)** | HK$37.7 million | 11.6% | 17.3% | | **Other Countries** | HK$74.7 million | 23.0% | 22.5% | [Financial Highlights](index=6&type=section&id=FINANCIAL%20HIGHLIGHTS) Driven by revenue growth, the Group's gross profit increased while key expenses were controlled, leading to a significant reduction in net loss Key Items in Statement of Profit or Loss | Financial Metric | H1 2021 | H1 2020 | Change YoY | | :--- | :--- | :--- | :--- | | **Revenue** | HK$324.8 million | HK$260.0 million | +24.9% | | **Cost of Sales** | HK$254.2 million | HK$201.5 million | +26.2% | | **Gross Profit** | HK$70.6 million | HK$58.5 million | +20.7% | | **Gross Profit Margin** | 21.7% | 22.5% | -0.8 ppt | | **Selling and Distribution Expenses** | HK$17.0 million | HK$27.6 million | -38.4% | | **Administrative Expenses** | HK$71.7 million | HK$72.6 million | -1.2% | | **Finance Costs** | HK$1.8 million | HK$3.0 million | -40.0% | | **Loss Attributable to Owners** | HK$32.0 million | HK$69.9 million | -54.2% | [Liquidity and Financial Resources](index=8&type=section&id=LIQUIDITY%20AND%20FINANCIAL%20RESOURCES) As of June 30, 2021, the Group maintained a sound financial position with increased cash reserves and an improved gearing ratio Liquidity and Financial Position Indicators (as of June 30, 2021) | Indicator | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Cash and Cash Equivalents** | HK$208.6 million | HK$167.7 million | | **Current Ratio** | 1.6 times | 1.6 times | | **Total Borrowings** | HK$20.6 million | HK$18.6 million | | **Gearing Ratio** | 52.1% | 55.0% | [Capital Structure and Financing Activities](index=9&type=section&id=CAPITAL%20STRUCTURE) The company successfully raised capital through two share placements during the period to fund operations and new business development - On January 11, 2021, the company successfully placed **85.58 million shares** at HK$0.35 per share, raising net proceeds of **HK$29.2 million**[36](index=36&type=chunk) - On June 30, 2021, the company successfully placed **102.7 million shares** at HK$0.224 per share, raising net proceeds of **HK$22.21 million**[37](index=37&type=chunk) - As of June 30, 2021, the total number of issued shares increased to **616,242,570** from 427,958,570 at the end of 2020[35](index=35&type=chunk) [Prospects](index=13&type=section&id=PROSPECTS) The Group is cautiously optimistic about its future, focusing on new growth in high-end healthcare services and leveraging policy changes - The Group has established a joint venture to engage in endometrial stem cell storage and fertility health management, marking a substantial move into the high-end medical field[62](index=62&type=chunk) - Management anticipates that China's **'three-child policy'** will create opportunities in the assisted reproduction and stem cell therapy markets, and the Group will actively integrate resources to capitalize on this trend[62](index=62&type=chunk) [Corporate Governance and Other Information](index=14&type=section&id=Corporate%20Governance%20and%20Other%20Information) [Corporate Governance](index=14&type=section&id=CORPORATE%20GOVERNANCE) The company complied with most Corporate Governance Code provisions but deviated by not separating the Chairman and CEO roles - The company deviated from Code Provision A.2.1 of the Corporate Governance Code, as the roles of **Chairman and Chief Executive Officer were not separated** and were both held by Mr. Lin Dailian[67](index=67&type=chunk)[68](index=68&type=chunk) [Share Option Scheme](index=16&type=section&id=Share%20Option%20Scheme) A new share option scheme was adopted in March 2020, under which over 35 million options were granted during the reporting period Details of Share Options Granted in H1 2021 | Category of Grantee | Name | Number of Options Granted | Exercise Price per Share (HK$) | Date of Grant | | :--- | :--- | :--- | :--- | :--- | | **Director** | Lin Dailian | 5,135,380 | 0.359 | January 28, 2021 | | **Director** | Xia Xiaobing | 5,135,380 | 0.359 | January 28, 2021 | | **Director** | Wang Guozhen | 5,135,380 | 0.359 | January 28, 2021 | | **Employee** | - | 20,265,710 | 0.359 | January 29, 2021 | | **Total** | - | **35,671,850** | - | - | - As of June 30, 2021, there were **35,671,850 outstanding share options** under the new share option scheme[84](index=84&type=chunk) [Interests of Directors and Major Shareholders](index=19&type=section&id=Interests%20and%20Short%20Positions%20of%20the%20Directors%20and%20Chief%20Executives) As of June 30, 2021, three executive directors held long positions through share options, while Power Port Holdings Limited was the largest shareholder Major Shareholders' Interests (as of June 30, 2021) | Name of Shareholder | Number of Shares Held | Percentage of Shareholding | | :--- | :--- | :--- | | Power Port Holdings Limited (Ms. Yang Changrong) | 75,817,000 | 12.30% | | Keywan Global Limited (Mr. He Xiaoming) | 49,500,000 | 8.03% | | Mr. Cao Longbing | 36,358,000 | 5.90% | | Hearts Capital SPC — Hearts SP2 | 35,930,000 | 5.83% | [Condensed Consolidated Financial Statements](index=22&type=section&id=Condensed%20Consolidated%20Financial%20Statements) [Condensed Consolidated Statement of Profit or Loss](index=22&type=section&id=Condensed%20Consolidated%20Statement%20of%20Profit%20or%20Loss) For the six months ended June 30, 2021, the company's revenue grew 24.9% year-on-year, leading to a significantly narrowed operating and total loss Summary of Statement of Profit or Loss for H1 2021 | Item (HK$'000) | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **Revenue** | 324,797 | 260,005 | | **Gross Profit** | 70,586 | 58,499 | | **Operating loss** | (28,274) | (61,705) | | **Loss before tax** | (30,060) | (67,762) | | **Loss for the period** | (32,129) | (69,922) | | **Loss attributable to owners of the Company** | (32,042) | (69,918) | | **Basic loss per share (HK cents)** | 7.02 | 20.52 | [Condensed Consolidated Statement of Financial Position](index=24&type=section&id=Condensed%20Consolidated%20Statement%20of%20Financial%20Position) As of June 30, 2021, the Group's total assets stood at HK$669.3 million, with total equity increasing due to new share issuance Summary of Statement of Financial Position (as of June 30, 2021) | Item (HK$'000) | June 30, 2021 | December 31, 2020 | | :--- | :--- | :--- | | **Total non-current assets** | 141,241 | 145,901 | | **Total current assets** | 528,017 | 511,504 | | **Total assets** | 669,258 | 657,405 | | **Total current liabilities** | 339,328 | 330,549 | | **Total liabilities** | 348,366 | 361,471 | | **Total equity** | 320,892 | 295,934 | [Condensed Consolidated Statement of Cash Flows](index=27&type=section&id=Condensed%20Consolidated%20Statement%20of%20Cash%20Flows) In H1 2021, net cash from financing and investing activities offset operating outflows, resulting in a net increase in cash and cash equivalents Summary of Cash Flows for H1 2021 | Item (HK$'000) | H1 2021 | H1 2020 | | :--- | :--- | :--- | | **Net cash used in operating activities** | (19,969) | (44,801) | | **Net cash from/(used in) investing activities** | 21,342 | (90,957) | | **Net cash from financing activities** | 39,117 | 27,988 | | **Net increase/(decrease) in cash and cash equivalents** | 40,490 | (47,115) | | **Cash and cash equivalents at end of period** | 208,621 | 194,226 | [Notes to the Condensed Financial Statements](index=28&type=section&id=Notes%20to%20the%20Condensed%20Financial%20Statements) [Note 4: Revenue and Segment Information](index=32&type=section&id=4.%20REVENUE%20AND%20SEGMENT%20INFORMATION) The Group's operations are divided into four segments, with Electronic Manufacturing Services (EMS) being the primary contributor to revenue and profit Performance by Business Segment for H1 2021 | Business Segment (HK$'000) | Revenue from external customers | Segment profit/(loss) | | :--- | :--- | :--- | | **Electronic Manufacturing Services (EMS)** | 297,985 | 10,635 | | **Distribution of communication products** | 23,909 | 310 | | **Investment in securities and other assets** | 340 | (17,257) | | **Real estate supply chain services** | 2,563 | (21,860) | | **Total** | **324,797** | **(28,172)** | [Note 23: Share Capital](index=49&type=section&id=23.%20SHARE%20CAPITAL) During the period, the company's issued and fully paid-up share capital increased following the placement of 188,284,000 new shares - On January 11, 2021, the company placed **85,580,000 new shares**, raising net proceeds of approximately **HK$29.35 million**[281](index=281&type=chunk) - On June 30, 2021, the company placed **102,704,000 new shares**, raising net proceeds of approximately **HK$22.32 million**[282](index=282&type=chunk) [Note 27: Events After the Reporting Period](index=52&type=section&id=27.%20EVENTS%20AFTER%20THE%20REPORTING%20PERIOD) Subsequent to the reporting period, the Group completed the disposal of its entire equity interest in one associate company in July 2021 - On March 23, 2021, the Group entered into agreements to dispose of its entire equity interests in associate companies Zhan Ju and Rong Shu[300](index=300&type=chunk) - The disposal of Zhan Ju was completed on **July 5, 2021**, after which the Group lost significant influence over the company[301](index=301&type=chunk) [Information for Investors](index=53&type=section&id=Information%20for%20Investors) - The company is listed on The Stock Exchange of Hong Kong Limited with the stock code 1143[310](index=310&type=chunk)

P LAIM Link-Asia International MedTech Link-Asia International MedTech Group Limited 環亞國際醫療科技集團有限公司 (formerly known as Link-Asia International Co. Ltd.) (前稱環亞國際實業有限公司) (incorporated in the Cayman Islands with limited liability 於開曼群島註冊成立的有限公司) (Stock Code 股份代號：1143) A CONTENTS 目錄 Corporate Information 公司資料 2 Financial Highlights 財務摘要 4 Chairman's Statement 主席報告書 5 Management Discussion and Analysis 管理層討論及分析 7 Corporate Governance Report 企業管治報告 25 Biographical Details of Directors 董事履歷詳情 40 Environmental, Soc ...

Financial Performance - For the six months ended June 30, 2020, the Group's revenue from continuing operations decreased by approximately HK$32.7 million, from approximately HK$292.7 million in 2019 to HK$260.0 million in 2020[7]. - The loss attributable to equity holders of the Company for the Period was approximately HK$69.9 million, representing an increase of 24.5% compared to a loss of approximately HK$56.2 million for the prior period[7]. - Total revenue from continuing operations for the period was approximately HK$260.0 million, a decrease of about 11.2% from HK$292.7 million in 2019[17]. - Loss for the period was HK$69,922,000, compared to a loss of HK$54,539,000 in the same period of 2019, representing a 28.3% increase in loss[148]. - Gross profit for the six months ended June 30, 2020, was HK$58,499,000, down from HK$59,724,000 in 2019, indicating a slight decline of 2.1%[143]. - Total comprehensive loss for the period was HK$87,116,000, compared to HK$44,546,000 in the same period of 2019, indicating a significant increase in overall loss[148]. Revenue Breakdown - The EMS business contributed approximately HK$231.2 million in revenue during the Period, down from HK$269.1 million in 2019[7]. - Revenue from the Distribution of Communication Products was approximately HK$15.8 million, a decrease from HK$17.9 million in 2019[7]. - The Real Estate Supply Chain Services segment contributed approximately HK$12.7 million in revenue for the Period, compared to nil in 2019[9]. - Revenue from major European countries totaled approximately HK$139.8 million, accounting for approximately 53.8% of total revenue, compared to 51.3% in 2019[12]. - The U.S. market contributed approximately HK$16.5 million, representing about 6.4% of total revenue, down from 13.2% in 2019[12]. - Revenue from the PRC (including Hong Kong) was approximately HK$45.0 million, accounting for about 17.3% of total revenue, an increase from 15.7% in 2019[12]. Expenses and Costs - Selling and distribution expenses from continuing operations were approximately HK$27.6 million in 2020, accounting for 10.6% of the Group's revenue, up from 5.6% in 2019[19]. - Administrative expenses from continuing operations decreased to approximately HK$72.6 million in 2020, representing 27.9% of revenue, compared to 26.3% in 2019[19]. - Other income from continuing operations decreased to HK$5.8 million, down from HK$6.8 million in 2019, primarily due to COVID-19 related impacts[17]. - Finance costs from continuing operations were approximately HK$3.0 million in 2020, representing 1.2% of revenue, a slight decrease from 1.1% in 2019[19]. Cash and Liquidity - As of June 30, 2020, the Group maintained bank and cash balances totaling HK$194.2 million, down from HK$241.4 million as of December 31, 2019[7]. - The Group's current ratio was 1.7 times as of 30 June 2020, down from 1.9 times in 2019, with cash and cash equivalents amounting to approximately HK$194.2 million[21]. - Cash and cash equivalents at the end of the period were HK$194,226,000, down from HK$375,348,000 at the end of June 2019[159]. Impact of COVID-19 - The Group's operations were significantly impacted by COVID-19, leading to production and delivery challenges[7]. - The board anticipates improvement in the real estate supply chain services segment as COVID-19 vaccines and treatments progress[13]. - The major economies experienced the largest quarterly contraction in decades during the first half of 2020 due to COVID-19 disruptions[66]. Share Capital and Equity - The total number of issued shares of the Company as of 30 June 2020 was 356,718,570, following a share consolidation[23]. - The share capital increased from HK$5,945,000 to HK$7,134,000, an increase of approximately 20.0%[153]. - Total equity attributable to owners of the Company decreased from HK$411,013,000 to HK$365,899,000, a decline of about 10.9%[153]. Investments and Acquisitions - The Group has started to expand into real estate advisory and purchase services in Southeast Asia and Pan Asia markets since the second half of 2019[7]. - The company made a deposit of HK$18,000,000 for exclusive agency rights in a Thailand real estate project[159]. - The company has no specific plans for material investments or capital assets as of June 30, 2020[44]. Governance and Compliance - The Company has complied with the Listing Rules regarding the composition of the Board and Audit Committee following the appointment of an independent non-executive Director on April 24, 2020[84]. - The company does not recommend the payment of an interim dividend for the period, consistent with 2019 where no dividend was paid[92]. - The Company’s corporate governance practices are in compliance with the relevant regulations and standards[119].

Financial Performance - For the year ended December 31, 2019, the Group reported revenue of HK$ 629.9 million, a decrease of 7.6% from HK$ 681.5 million in 2018[19]. - The loss for the year was HK$ 179.3 million, compared to a loss of HK$ 49.3 million in 2018, indicating a significant decline in profitability[19]. - Loss attributable to owners of the Company was HK$ 171.7 million, up from HK$ 58.0 million in the previous year[19]. - The Group's total revenue from continuing operations for the year was approximately HK$629.9 million, a decrease from HK$681.5 million in 2018, representing a decline of about 7.3%[33]. - Gross profit from continuing operations amounted to approximately HK$135.8 million, down from HK$147.3 million in 2018, indicating a decrease of approximately 7.9%[33]. - The loss attributable to owners of the Company was approximately HK$171.8 million, compared to a loss of HK$58.0 million in 2018, reflecting a significant increase in losses[33]. - Revenue from the EMS segment decreased by approximately 6.5% to HK$582.5 million, while the Distribution of Communications Products segment saw a decline of approximately 16.6% to HK$36.5 million[49]. - The Group's finance costs increased to approximately HK$6.8 million in 2019 from HK$2.8 million in 2018, representing 1.1% and 0.4% of revenue from continuing operations, respectively[60][65]. Asset and Liability Management - The Group's total assets decreased to HK$ 734.8 million from HK$ 930.9 million, while total liabilities slightly decreased to HK$ 323.9 million from HK$ 348.0 million[19]. - As of December 31, 2019, the Group had bank and cash balances totaling approximately HK$241.4 million, down from HK$354.2 million in 2018, indicating a decrease of about 31.8%[36]. - The current ratio of the Group was 1.9 times as of December 31, 2019, down from 2.15 times in 2018, indicating a slight decline in liquidity[69]. - The gearing ratio increased to 44.1% as of December 31, 2019 from 37.4% in 2018, calculated based on total liabilities divided by total assets[71][75]. Strategic Developments - The Group officially changed its name to Link-Asia International Co. Ltd. on November 20, 2019, as part of its future development strategy[23]. - The Group has begun to explore opportunities in the real estate supply chain service business in Southeast Asia since the second half of 2019, targeting local development and asset allocation needs[23]. - The Group has shifted its business focus towards the Southeast Asia real estate supply chain, leveraging its network to identify high-quality projects since the second half of 2019[32]. - The Group aims to consolidate resources and seek new business opportunities to provide reasonable returns to shareholders amidst challenging economic conditions[28]. Market Conditions - China's GDP growth fell to 6.1% in 2019, the lowest since 1990, impacting the Group's export business and overall performance[22]. - The Group will continue to monitor negative impacts from geopolitical conflicts and seek quality investment opportunities for sustainable development[22]. - The Group's operating environment has been significantly affected by the COVID-19 outbreak, leading to market volatility[117]. - The Group anticipates a severe contraction in the economy due to the ongoing pandemic[119]. Governance and Compliance - Mr. Wong Chun Hung resigned as an independent non-executive Director on 12 August 2019, leading to a temporary non-compliance with Listing Rules regarding the minimum number of independent non-executive Directors[131]. - The Company appointed Mr. Li Huiwu as an independent non-executive Director and chairman of the Audit Committee on 14 October 2019, restoring compliance with Listing Rules 3.10(1), 3.10A, and 3.21[133]. - The Board currently consists of three Executive Directors and three Independent Non-executive Directors, with the latter accounting for over one-third of the Board[145]. - The Company has adopted the Model Code for Securities Transactions by Directors, with all Directors confirming compliance throughout the year ended 31 December 2019[134]. - The Company has complied with Listing Rules 3.10(1) and (2) since the Listing Date, maintaining a balanced and independent Board composition[145]. Risk Management - The Group is exposed to market risks, including fluctuations in foreign exchange rates, interest rates, and equity prices, and currently does not have a foreign currency hedging policy[101][102]. - The Group is closely monitoring liquidity risk by maintaining adequate cash levels to finance operations[109]. - The Group is managing interest rate risk dynamically to ensure cost-effective risk management[108]. - The Group faces manpower and retention risks, and will provide attractive remuneration packages to retain key personnel[111]. Employee and Community Engagement - The Group had approximately 1,400 employees as of 31 December 2019, offering competitive remuneration packages and training programs to attract and retain talent[92]. - The Group is committed to maintaining high environmental and social standards, encouraging participation in community activities, and complying with environmental laws[94][95].

HEALTHCARE 华 | 夏 | 健 | 康 China Healthcare Enterprise Group Limited 華夏健康產業集團有限公司 (Incorporated in the Cayman Islands with limited liability) (於開曼群島註冊成立的有限公司) Stock Code 股份代號 : 1143 INTERIM REPORT 中期報告 N Z M N H M N a a marker t H B Contents 目錄 Corporate Information 公司資料 2 | --- | --- | --- | |-----------------------------------------------------------------------------------|-----------------------------------|-------| | | | | | Management Discussion and Analysis | 管理層討論及分析 | 4 | | Corporate Governance and O ...